Compounds / GH Axis / Tesamorelin

Tesamorelin

Tesamorelin (Stabilized GHRH Analog — Egrifta)
GH AxisFDA ApprovedFDA: FDA-APPROVED (Egrifta) for...WADA: PROHIBITED — Category S2

Overview

FDA-approved (Egrifta). ~15% visceral fat reduction in HIV patients. Improved lipid profiles. Also studied for age-related GH decline and abdominal obesity.

Mechanism of Action

Trans-3-hexenoic acid modification stabilizes GHRH analog. Reduces visceral adipose tissue. FDA-approved specifically for HIV-associated lipodystrophy excess abdominal fat.

Pharmacokinetics

Half-life
26 min
Peak (Tmax)
9 min
Cleared
~2.1 hrs

Molecular Profile

Molecular weight
5,135.9 Da
CAS number
218949-48-5
Type
GHRH analog
Length
44 amino acids
His-Ala-Asp-Gly-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-

Key Research Findings

~15% visceral fat reduction; improved lipids; FDA-approved; HIV lipodystrophy treatment.

Published Research

Drugs (2011)
Dhillon S. Tesamorelin: A Review of Its Use in HIV-Associated Lipodystrophy
View source

Related GH Axis Compounds

IpamorelinCJC-1295 (No DAC)CJC-1295 (DAC)SermorelinGHRP-2GHRP-6
Clinical Guidance

Research data is not a treatment plan. If you are considering Tesamorelin, the questions that matter are whether it suits your history, your labs and your goals. That is a conversation with a licensed physician, not a lookup.

Speak with a physician LATOM Wellness is a physician-led telehealth practice. Consultation only. No compound is sold on this site.
Running Tesamorelin? Log doses and track your cycle.

Interactive tools for this compound:

Reconstitution calculator  ·  Full deep dive  ·  Peptide fundamentals